Nebenwirkungen · Duavive
DUAVIVE 0.45 mg/20 mg modified-release tablets · Abschnitt 4.8 · PDF-Seite 10
HOS-125241 · Präparat HOS-096029
Estimated additional risk of breast cancer after 5 years’ use in women with BMI 27 (kg/m 2) Incidence per 1,000 Additional cases per Age at start never-users of HRT over Risk ratio 1,000 HRT users after HRT (years) a 5 year period (50-54 5 years years)* Oestrogen only 50 13.3 1.2 2.7 * Taken from baseline incidence rates in England in 2015 in women with BMI 27 Note: Since the background incidence of breast cancer differs by EU country, the number of additional cases of breast cancer will also change proportionately.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-06T02:00:00Z · SHA-256 cebc18aeeaa7e87d26ff41a36f1789bee3f7e1eaa839d2f6fdebebc62c1ef614 · Passage 686548519edfae2b7b67ef32434a643bb1d64d62f8f3df926f666c6c85b92224 · Zeichen 3443–4258 im Abschnitt